ScholarIQanswers from OpenAlex
International Drug Development Institute (Belgium)
InstitutionResearch output, impact & collaborations
International Drug Development Institute (Belgium) is a institution indexed in ScholarIQ from OpenAlex.
What is known about International Drug Development Institute (Belgium)?
ScholarIQrecord summary
International Drug Development Institute (Belgium) is a research organisation in Brussels, BE. OpenAlex records 514 works and 160,214 citations for it. 68 researchers list it as their most recent affiliation.
How many works does International Drug Development Institute (Belgium) have?
ScholarIQindexed works
International Drug Development Institute (Belgium) has 514 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does International Drug Development Institute (Belgium) have?
ScholarIQcitation count
International Drug Development Institute (Belgium) has 160,214 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at International Drug Development Institute (Belgium)?
ScholarIQresearcher count
International Drug Development Institute (Belgium) has 68 researchers in the ScholarIQ index.
What is the average h-index at International Drug Development Institute (Belgium)?
ScholarIQavg h-index
International Drug Development Institute (Belgium) has an average h-index of 100 in OpenAlex.
What is the ROR of International Drug Development Institute (Belgium)?
ScholarIQror
The ROR for International Drug Development Institute (Belgium) is on the source record.
What is the OpenAlex record for International Drug Development Institute (Belgium)?
ScholarIQopenalex
The OpenAlex for International Drug Development Institute (Belgium) is on the source record.
Who are the most-cited researchers behind International Drug Development Institute (Belgium)?
ScholarIQtop researchers by citations
What are the most-cited papers on International Drug Development Institute (Belgium)?
ScholarIQmost cited works
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis J. Slamon, W. Eiermann, Nicholas J. Robert, Tadeusz Pieńkowski, Miguel Martín, Michael F. Press, John R. Mackey, John A. Glaspy, Arlene Chan, Marek Pawlicki, Tamás Pintér, Vicente Valero, Mei-Ching Liu, Guido Sauter, Gϋnter von Minckwitz, F. Visco, Valerie Bée, Marc Buyse, Belguendouz Bendahmane, Isabelle Tabah-Fisch, Mary-Ann Lindsay, A. Riva, John Crown
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gϋnter von Minckwitz, Stephen Chia, Janine Mansi, Carlos H. Barrios, Michael Gnant, Z. Tomasevic, Neelima Denduluri, Robert Šeparović, Erhan Gökmen, Anna Bashford, Manuel Ruíz Borrego, Sung‐Bae Kim, Erik Jakobsen, A. Ciceniene, Kenichi Inoue, Friedrich Overkamp, Joan B. Heijns, Anne Armstrong, John S. Link, Anil A. Joy, Richard Bryce, Alvin Wong, Susan Moran, Bin Yao, Feng Xu, Alan Auerbach, Marc Buyse, Arlene Chan, Vernon Harvey, Rudolf Tomek, Nicholas J. Robert, Ira Gore, John W. Smith, Norikazu Masuda, S. Di Sean Kendall, William Graydon Harker, Katarína Petráková, Ángel Guerrero‐Zotano, Amparo Ruiz Simón, Zora Neskovic Konstantinovic, Nicholas Iannotti, Pierfrancesco Tassone, Gladys Rodriguez, Noelia Jáñez Martínez, Carmen Crespo Massieu, Snezana Smickoska, Işıl Somali, Uğur Yılmaz, Mirta Garcia Alonso, Adolfo Rosales, Soeren Cold, Ann Knoop, Debra A. Patt, Beth A. Hellerstedt, Serafin Morales Murillo, Ingrid A. Mayer, Julie A. Means‐Powell, Rina Hui, Francis M. Senecal, Richard Hendry De Boer, Zhenzhou Shen, A.A. Luczak, Joanna W.Y. Chui, Janice Tsang, István Láng, Yoshiaki Rai, Yasuo Hozumi, Albert J. ten Tije, Manish Bhandari, Cynthia R. Osborne, Shoichiro Ohtani, Kenji Higaki, Kenichi Watanabe, Kazunori TAGUCHI, Masato Takahashi, Sladjana Filipovic, Vincent Hansen, Vijayarama Phooshkooru Rao, Manish Gupta, Petar Petrov, Bruno Coudert, Željko Vojnović, Zsofia Polya, Toshiko Miyaki, Naohito Yamamoto, Stephen Brincat, Krzysztof Leśniewski-Kmak, Ewa Chmielowska, Ruemu Birhiray, Marc L. Citron, Steven W. Papish, William L. Berry, Sven Tyge Langkjer, José Á. García-Sáenz
[The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use].
Jean‐Paul Boissel, Michel Cucherat, Wei Li, Gilles Châtellier, François Gueyffier, Marc Buyse, Florent Boutitie, Patrice Nony, M. Haugh, G Mignot
Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer
Howard I. Scher, Glenn Heller, Arturo Molina, Gerhardt Attard, Daniel C. Danila, Xiaoyu Jia, Weimin Peng, Shahneen Sandhu, David Olmos, Ruth Riisnaes, Robert G. McCormack, Tomasz Burzykowski, Thian Kheoh, Martin Fleisher, Marc Buyse, Johann S. de Bono
The value of preoperative radiotherapy in esophageal cancer: Results of a study of the E.O.R.T.C.
M Gignoux, A Roussel, B Paillot, M Gillet, P. Schlag, Jean‐Pierre Favre, Otilia Dalesio, Marc Buyse, N. Duez
How much of the research on International Drug Development Institute (Belgium) is open access?
ScholarIQopen access share
40%OPEN ACCESS